S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Improve Mental Health Next Year by Breaking 17 Financial Rules
Next-Generation Fighter Jets?!? (Must See) (Ad)pixel
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
Next-Generation Fighter Jets?!? (Must See) (Ad)pixel
Can ZIM Defy Broad Downturn In The Container Shipping Industry?
China fines former NBA star Lin over quarantine comments
Next-Generation Fighter Jets?!? (Must See) (Ad)pixel
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Improve Mental Health Next Year by Breaking 17 Financial Rules
Next-Generation Fighter Jets?!? (Must See) (Ad)pixel
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
Next-Generation Fighter Jets?!? (Must See) (Ad)pixel
Can ZIM Defy Broad Downturn In The Container Shipping Industry?
China fines former NBA star Lin over quarantine comments
Next-Generation Fighter Jets?!? (Must See) (Ad)pixel
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Improve Mental Health Next Year by Breaking 17 Financial Rules
Next-Generation Fighter Jets?!? (Must See) (Ad)pixel
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
Next-Generation Fighter Jets?!? (Must See) (Ad)pixel
Can ZIM Defy Broad Downturn In The Container Shipping Industry?
China fines former NBA star Lin over quarantine comments
Next-Generation Fighter Jets?!? (Must See) (Ad)pixel
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Improve Mental Health Next Year by Breaking 17 Financial Rules
Next-Generation Fighter Jets?!? (Must See) (Ad)pixel
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
Next-Generation Fighter Jets?!? (Must See) (Ad)pixel
Can ZIM Defy Broad Downturn In The Container Shipping Industry?
China fines former NBA star Lin over quarantine comments
Next-Generation Fighter Jets?!? (Must See) (Ad)pixel
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
OTCMKTS:ASPCF

Acerus Pharmaceuticals - ASPCF Stock Forecast, Price & News

$0.85
0.00 (0.00%)
(As of 12/2/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.85
$0.85
50-Day Range
$0.85
$1.85
52-Week Range
$0.85
$8.16
Volume
N/A
Average Volume
25 shs
Market Capitalization
$6.55 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ASPCF stock logo

About Acerus Pharmaceuticals (OTCMKTS:ASPCF) Stock

Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; and Noctiva, a vasopressin analog indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Tefina, a clinical stage product for women with female sexual dysfunction; and Noctiva combination products, which are in the pre-clinical development stage for the treatment of benign prostatic hypertrophy, overactive bladder, and pediatric nocturnal enuresis. In addition, the company provides TriVair technology platform for pulmonary and nasal dosing. It sells its products through its salesforce in the United States and Canada; and through a network of distributors internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.

Receive ASPCF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acerus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ASPCF Stock News Headlines

Acerus Reports Third Quarter 2022 Financial Results
Acerus Announces Initiation of Strategic Review
Acerus Announces Completion of Share Consolidation
Acerus Announces Share Consolidation
See More Headlines
Receive ASPCF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acerus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ASPCF Company Calendar

Last Earnings
11/14/2022
Today
12/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:ASPCF
CIK
N/A
Employees
14
Year Founded
N/A

Profitability

Net Income
$-33,820,000.00
Net Margins
-924.33%
Pretax Margin
-1,008.97%

Debt

Sales & Book Value

Annual Sales
$2.12 million
Book Value
($3.38) per share

Miscellaneous

Free Float
N/A
Market Cap
$6.55 million
Optionable
Not Optionable
Beta
0.59

Key Executives

  • Mr. Edward Gudaitis
    Pres, CEO & Director
  • Mr. Gavin Damstra
    Sr. VP of International Commercial
  • Dr. Christopher Sorli F.A.C.E.
    M.D., Ph.D., Chief Medical Officer
  • Mr. Kevin Thomas Hickey
    Sr. VP of US Commercial
  • Mr. Naveed Manzoor
    Interim Chief Financial Officer
  • Mr. Chris Witty
    Investor Relations
  • Mr. Philippe Savard
    Sr. VP, Gen. Counsel & Corp. Sec.
  • Mr. Hubert Tomasz Czerwinski
    Pres of Acerus Pharmaceuticals SRL













ASPCF Stock - Frequently Asked Questions

How have ASPCF shares performed in 2022?

Acerus Pharmaceuticals' stock was trading at $4.06 on January 1st, 2022. Since then, ASPCF stock has decreased by 79.1% and is now trading at $0.85.
View the best growth stocks for 2022 here
.

Are investors shorting Acerus Pharmaceuticals?

Acerus Pharmaceuticals saw a increase in short interest in the month of October. As of October 31st, there was short interest totaling 1,400 shares, an increase of 100.0% from the October 15th total of 700 shares. Based on an average daily volume of 100 shares, the days-to-cover ratio is presently 14.0 days.
View Acerus Pharmaceuticals' Short Interest
.

How were Acerus Pharmaceuticals' earnings last quarter?

Acerus Pharmaceuticals Co. (OTCMKTS:ASPCF) issued its earnings results on Monday, November, 14th. The company reported ($0.54) earnings per share (EPS) for the quarter. The company had revenue of $0.77 million for the quarter.

When did Acerus Pharmaceuticals' stock split?

Acerus Pharmaceuticals shares reverse split on the morning of Friday, April 29th 2022. The 1-200 reverse split was announced on Friday, April 29th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

What is Acerus Pharmaceuticals' stock symbol?

Acerus Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ASPCF."

How do I buy shares of Acerus Pharmaceuticals?

Shares of ASPCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Acerus Pharmaceuticals' stock price today?

One share of ASPCF stock can currently be purchased for approximately $0.85.

How much money does Acerus Pharmaceuticals make?

Acerus Pharmaceuticals (OTCMKTS:ASPCF) has a market capitalization of $6.55 million and generates $2.12 million in revenue each year. The company earns $-33,820,000.00 in net income (profit) each year or ($3.57) on an earnings per share basis.

How can I contact Acerus Pharmaceuticals?

Acerus Pharmaceuticals' mailing address is 2486 Dunwin Drive, Mississauga A6, L5L 1J9. The official website for the company is www.aceruspharma.com. The company can be reached via phone at (416) 679-0771, via email at ir@aceruspharma.com, or via fax at 905-569-1809.

This page (OTCMKTS:ASPCF) was last updated on 12/3/2022 by MarketBeat.com Staff